# EDGAR Filing Document

**Accession Number:** 0001127703
**File Stem:** 0001127703-26-000006
**Filing Date:** 2026-2
**Character Count:** 59483
**Document Hash:** f37ffec99a9e0c7623fc211628869370
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001127703-26-000006.hdr.sgml**: 20260223

**ACCESSION NUMBER**: 0001127703-26-000006

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20260223

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260223

**DATE AS OF CHANGE**: 20260223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PROASSURANCE CORP
- **CENTRAL INDEX KEY:** 0001127703
- **STANDARD INDUSTRIAL CLASSIFICATION:** FIRE, MARINE & CASUALTY INSURANCE [6331]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 631261433
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-16533
- **FILM NUMBER:** 26665378

**BUSINESS ADDRESS:**
- **STREET 1:** 100 BROOKWOOD PLACE
- **CITY:** BIRMINGHAM
- **STATE:** AL
- **ZIP:** 35209
- **BUSINESS PHONE:** 2058774400

**MAIL ADDRESS:**
- **STREET 1:** 100 BROOKWOOD PLACE
- **CITY:** BIRMINGHAM
- **STATE:** AL
- **ZIP:** 35209

?xml version='1.0' encoding='ASCII'? pra-20260223

---

| | |
|:---|:---|
| UNITED STATES | UNITED STATES |
| SECURITIES AND EXCHANGE COMMISSION | SECURITIES AND EXCHANGE COMMISSION |
| Washington, D.C. 20549 | Washington, D.C. 20549 |
| FORM | 8-K |
| CURRENT REPORT | CURRENT REPORT |
| Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 | Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 |
| Date of Report (Date of earliest event reported): February 23, 2026 | Date of Report (Date of earliest event reported): February 23, 2026 |
| ![PRA-Group-SIC-Logo-CMYK.jpg](pra-20260223_g1.jpg) | ![PRA-Group-SIC-Logo-CMYK.jpg](pra-20260223_g1.jpg) |
| ProAssurance Corporation | ProAssurance Corporation |
| (Exact name of registrant as specified in its charter) | (Exact name of registrant as specified in its charter) |

---

Delaware 001-16533 63-1261433 <br> (State of Incorporation) (Commission File No.) (IRS Employer I.D. No.)

100 Brookwood Place, Birmingham, AL 35209 <br> (Address of Principal Executive Office) (Zip code)

Registrant's telephone number, including area code: (205) 877-4400

---

| | |
|:---|:---|
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Securities Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act <br>(17CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-(c) under the Exchange Act <br>(17CFR 240.13e-(c)) |

---

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | PRA | New York Stock Exchange |

---

---

| | |
|:---|:---|
| Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Emerging growth company | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻ |

---

&nbsp;&nbsp;&nbsp;&nbsp;1

------

**ITEM 2.02 RESULTS OF OPERATION AND FINANCIAL CONDITION**

On February 23, 2026 we issued a news release reporting the results of our operations for the quarter and year ended December 31, 2025. The text of the release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

<u>[99.1 News release issued on February 23, 2026 reporting results of ProAssurance's operations for the quarter ended December 31, 2025.](pra-20251231xex991xmaster.htm)</u>

The information we are furnishing under Item 9.01 of this Current Report on Form 8K, including Exhibit 99.1, is not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the "Exchange Act") as amended, or otherwise subject to the liability of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 23, 2026

---

| |
|:---|
| PROASSURANCE CORPORATION |
| by: /s/ Jeffrey P. Lisenby |
| ----------------------------------------------------- |
| Jeffrey P. Lisenby<br>General Counsel |

---

&nbsp;&nbsp;&nbsp;&nbsp;2

## Exhibit 99.1

---

| | |
|:---|:---|
| **NEWS RELEASE**<br>For More Information:<br>Heather J. Wietzel • SVP, Investor Relations<br>800-282-6242 • 205-776-3028 • InvestorRelations@ProAssurance.com | ![pra-groupxsicxlogoxrgbtran.jpg](pra-groupxsicxlogoxrgbtran.jpg) |

---

**ProAssurance Reports Results for Fourth Quarter and <br>Full-Year 2025**

**BIRMINGHAM, AL – February 23, 2026 – ProAssurance Corporation (NYSE: PRA),** an industry-leading specialty insurer with extensive expertise in medical professional liability, today reported net income of $33.4 million, or $0.64 per diluted share, and operating income<sup>(1)</sup> of $42.4 million, or $0.82 per diluted share, for the three months ended December 31, 2025. For the year ended December 31, 2025, net income was $50.9 million, or $0.99 per diluted share, and operating income was $83.9 million, or $1.62 per diluted share.

**Highlights**<sup>(2)</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating performance continues to demonstrate progress toward premium rate levels appropriate for the challenging conditions in the medical professional liability and workers' compensation markets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net Income was impacted by non-operating items totaling $9.0 million and $32.9 million for the quarter and year ended December 31, 2025, respectively, which are discussed under "Reconciliation of Net Income (Loss) to Non-GAAP Operating Income (Loss)."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated net premiums written were $916.9 million for the year, including net premiums written of $673.6 million for our Medical Professional Liability business, which makes up over 95% of the Specialty P&C segment, and $167.3 million for the Workers' Compensation Insurance segment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Specialty P&C renewal premium increases of 8% for 2025 are part of the cumulative premium change of more than 80% we have accomplished since 2018 in the medical professional liability market. Retention for the entire Specialty P&C segment was 84% for the year, unchanged from the prior year. We continue to forgo renewal and new business opportunities when we believe they do not meet our expectation of rate adequacy in the current medical professional liability loss environment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated Non-GAAP combined ratio for the full-year 2025 improved 4.8 points for 2025 to 104.2%, including a 98.3% Non-GAAP combined ratio for the Specialty P&C segment<sup>(1)</sup>. The consolidated Non-GAAP combined ratio<sup>(1)</sup> was 90.3% in the fourth quarter, largely due to the effect of favorable prior year reserve development, primarily related to $53.1 million of favorable development in our Medical Professional Liability business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated net investment income increased 8.3% for the year, reflecting higher average book yields. Earnings from limited partnership investments (reported as equity in earnings of unconsolidated subsidiaries) were below the prior year due to lower market valuations for two holdings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Book value per share was $26.24 at December 31, 2025, up $2.75 from $23.49 at year-end 2024; Non-GAAP adjusted book value per share<sup>(1)</sup> was $27.82 compared with $26.86 at year-end 2024.

"We continue to see progress toward our objectives," said Ned Rand, President and Chief Executive Officer of ProAssurance. "Joining forces with The Doctors Company through the transaction we announced in March 2025 will allow our organizations to continue to serve today's healthcare providers with the necessary scale and breadth of capabilities.

"Closing the transaction remains subject to approval from insurance regulators in the jurisdictions where we have operating subsidiaries domiciled. To date, The Doctors Company has received final approval from insurance regulators in Alabama, the District of Columbia, Illinois, Missouri, Texas and Vermont. Review of the proposed transaction by insurance regulators remains pending in California and Pennsylvania. The timing for completion of the pending reviews is uncertain and outside our control, but in light of progress made, we continue to anticipate closing the transaction by June 30, 2026," Rand added. "The Federal Trade Commission granted the transaction early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in July and ProAssurance shareholders overwhelmingly approved the transaction in June."

<sup>(1)</sup> Represents a Non-GAAP financial measure that excludes certain items that are not indicative of the performance of our ongoing core operations. See a reconciliation of the Non-GAAP financial measure to its GAAP counterpart under the heading "Non-GAAP Financial Measures" that follows.

<sup>(2)</sup> Comparisons are to full-year 2024 unless otherwise noted.

&nbsp;&nbsp;&nbsp;&nbsp;- more -&nbsp;&nbsp;&nbsp;&nbsp;Page: 1

------

**NEWS RELEASE CONTINUES**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **CONSOLIDATED INCOME STATEMENT HIGHLIGHTS** | **CONSOLIDATED INCOME STATEMENT HIGHLIGHTS** | **CONSOLIDATED INCOME STATEMENT HIGHLIGHTS** | **CONSOLIDATED INCOME STATEMENT HIGHLIGHTS** | **CONSOLIDATED INCOME STATEMENT HIGHLIGHTS** | **CONSOLIDATED INCOME STATEMENT HIGHLIGHTS** | **CONSOLIDATED INCOME STATEMENT HIGHLIGHTS** |
| Selected consolidated financial data for each period is summarized in the table below.  | Selected consolidated financial data for each period is summarized in the table below.  | Selected consolidated financial data for each period is summarized in the table below.  | Selected consolidated financial data for each period is summarized in the table below.  | Selected consolidated financial data for each period is summarized in the table below.  | Selected consolidated financial data for each period is summarized in the table below.  | Selected consolidated financial data for each period is summarized in the table below.  |
|  | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** |
| ($ in thousands, except per share data) | **<u>2025</u>** | <u>2024</u> | *<u>Change</u>* | **<u>2025</u>** | <u>2024</u> | *<u>Change</u>* |
| **Revenues** |  |  |  |  |  |  |
| Gross premiums written<sup>(1)</sup> | $**201517** | $207673 | *(3.0 %)* | $**1012705** | $1050867 | *(3.6 %)* |
| Net premiums written | $**183884** | $188545 | *(2.5 %)* | $**916913** | $953675 | *(3.9 %)* |
| Net premiums earned | $**232149** | $241074 | *(3.7 %)* | $**934236** | $968250 | *(3.5 %)* |
| Net investment income | **40172** | 36811 | *9.1 %* | **156498** | 144538 | *8.3 %* |
| Equity in earnings (loss) of unconsolidated subsidiaries | **2946** | 5820 | *(49.4 %)* | **16276** | 22203 | *(26.7 %)* |
| Net investment gains (losses)<sup>(2)</sup> | **(4861)** | (3243) | *(49.9 %)* | **(5486)** | 1903 | *(388.3 %)* |
| Other income (expense)<sup>(1)</sup> | **(765)** | 9638 | *(107.9 %)* | **(3496)** | 13510 | *(125.9 %)* |
| &nbsp;&nbsp;Total revenues<sup>(1)</sup> | **269641** | 290100 | *(7.1 %)* | **1098028** | 1150404 | *(4.6 %)* |
| **Expenses** |  |  |  |  |  |  |
| Net losses and loss adjustment expenses | **129320** | 182410 | *(29.1 %)* | **665418** | 739435 | *(10.0 %)* |
| Underwriting, policy acquisition and operating expenses<sup>(1)</sup> | **84894** | 80927 | *4.9 %* | **330417** | 319339 | *3.5 %* |
| SPC U.S. federal income tax expense (benefit) | **501** | 724 | *(30.8 %)* | **2413** | 1766 | *36.6 %* |
| SPC dividend expense (income) | **3112** | 1965 | *58.4 %* | **6873** | 4444 | *54.7 %* |
| Interest expense | **5218** | 5339 | *(2.3 %)* | **20838** | 22342 | *(6.7 %)* |
| &nbsp;&nbsp;Total expenses<sup>(1)</sup> | **223045** | 271365 | *(17.8 %)* | **1025959** | 1087326 | *(5.6 %)* |
| Income (loss) before income taxes | **46596** | 18735 | *148.7 %* | **72069** | 63078 | *14.3 %* |
| Income tax expense (benefit) | **13227** | 2566 | *415.5 %* | **21154** | 10334 | *104.7 %* |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | $**33369** | $16169 | *106.4 %* | $**50915** | $52744 | *(3.5 %)* |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP operating income (loss)<sup>(3)</sup> | $**42389** | $19744 | *114.7 %* | $**83863** | $50171 | *67.2 %* |
| **Weighted average number of common shares outstanding** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | **51414** | 51156 |  | **51341** | 51097 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | **51795** | 51411 |  | **51669** | 51266 |  |
| **Earnings (loss) per share** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) per diluted share | $**0.64** | $0.31 | $*0.33* | $**0.99** | $1.03 | $*(0.04)* |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP operating income (loss) per diluted share | $**0.82** | $0.38 | $*0.44* | $**1.62** | $0.98 | $*0.64* |

---

<sup>(1)</sup> Consolidated totals include inter-segment eliminations. The eliminations affect individual line items only and have no effect on net income (loss). See Note 15 of the Notes to Consolidated Financial Statements in our December 31, 2025 report on Form 10-K for amounts by line item.

<sup>(2)</sup> This line item typically includes both realized and unrealized investment gains and losses and investment impairments losses. Detailed information regarding the components of net investment gains (losses) are included in Note 3 of the Notes to Consolidated Financial Statements in our December 31, 2025 report on Form 10-K.

<sup>(3)</sup> See a reconciliation of net income (loss) to Non-GAAP operating income (loss) under the heading "Non-GAAP Financial Measures" that follows.

The abbreviation "*nm*" indicates that the information or the percentage change is not meaningful.

&nbsp;&nbsp;&nbsp;&nbsp;- more -&nbsp;&nbsp;&nbsp;&nbsp;Page: 2

------

**NEWS RELEASE CONTINUES**

---

| | | |
|:---|:---|:---|
| **BALANCE SHEET HIGHLIGHTS** | **BALANCE SHEET HIGHLIGHTS** | **BALANCE SHEET HIGHLIGHTS** |
| ($ in thousands, except per share data) | **<u>December 31, 2025</u>** | <u>December 31, 2024</u> |
| Total investments | $**4429379** | $4367427 |
| Total assets | $**5447192** | $5574273 |
| Total liabilities | $**4098058** | $4372524 |
| Common shares (par value $0.01) | $**640** | $638 |
| Retained earnings | $**1485640** | $1434725 |
| Treasury shares | $**(469694)** | $(469694) |
| Shareholders' equity | $**1349134** | $1201749 |
| Book value per share | $**26.24** | $23.49 |
| Non-GAAP adjusted book value per share<sup>(1)</sup> | $**27.82** | $26.86 |
| <sup>(1)</sup> Adjusted book value per share is a Non-GAAP financial measure. See a reconciliation of book value per share to Non-GAAP adjusted book value per share under the heading "Non-GAAP Financial Measures" that follows. | <sup>(1)</sup> Adjusted book value per share is a Non-GAAP financial measure. See a reconciliation of book value per share to Non-GAAP adjusted book value per share under the heading "Non-GAAP Financial Measures" that follows. | <sup>(1)</sup> Adjusted book value per share is a Non-GAAP financial measure. See a reconciliation of book value per share to Non-GAAP adjusted book value per share under the heading "Non-GAAP Financial Measures" that follows. |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **CONSOLIDATED KEY RATIOS** | **CONSOLIDATED KEY RATIOS** | **CONSOLIDATED KEY RATIOS** | **CONSOLIDATED KEY RATIOS** | **CONSOLIDATED KEY RATIOS** |
| | **Three Months Ended December 31** | **Three Months Ended December 31** | **Year Ended December 31** | **Year Ended December 31** |
|  | **<u>2025</u>** | <u>2024</u> | **<u>2025</u>** | <u>2024</u> |
| Current accident year net loss ratio | **81.7%** | 80.4% | **80.9%** | 80.5% |
| Effect of prior accident years' reserve development | **(26.0** **%)** | (4.7%) | **(9.7** **%)** | (4.1%) |
| Net loss ratio | **55.7%** | 75.7% | **71.2%** | 76.4% |
| Underwriting expense ratio | **36.6%** | 33.6% | **35.4%** | 33.0% |
| Combined ratio | **92.3%** | 109.3% | **106.6%** | 109.4% |
| Non-GAAP combined ratio<sup>(1)</sup> | **90.3%** | 106.0% | **104.2%** | 109.0% |
| Operating ratio | **75.0%** | 94.0% | **89.8%** | 94.5% |
| Non-GAAP operating ratio<sup>(1)</sup> | **73.0%** | 90.5% | **87.4%** | 93.7% |
| Return on equity<sup>(2)</sup> | **10.1%** | 5.3% | **4.0%** | 4.6% |
| Non-GAAP operating return on equity<sup>(1)(2)</sup> | **12.8%** | 6.5% | **6.6%** | 4.4% |
| <sup>(1)</sup> Represents a Non-GAAP financial measure. See a reconciliation to their GAAP counterparts under the heading "Non-GAAP Adjusted Key Ratios" that follows. | <sup>(1)</sup> Represents a Non-GAAP financial measure. See a reconciliation to their GAAP counterparts under the heading "Non-GAAP Adjusted Key Ratios" that follows. | <sup>(1)</sup> Represents a Non-GAAP financial measure. See a reconciliation to their GAAP counterparts under the heading "Non-GAAP Adjusted Key Ratios" that follows. | <sup>(1)</sup> Represents a Non-GAAP financial measure. See a reconciliation to their GAAP counterparts under the heading "Non-GAAP Adjusted Key Ratios" that follows. | <sup>(1)</sup> Represents a Non-GAAP financial measure. See a reconciliation to their GAAP counterparts under the heading "Non-GAAP Adjusted Key Ratios" that follows. |
| <sup>(2)</sup> Quarterly amounts are annualized. Refer to our December 31, 2025 report on Form 10-K under the heading "Non-GAAP Operating ROE" in the Executive Summary of Operations section for details on our calculation.  | <sup>(2)</sup> Quarterly amounts are annualized. Refer to our December 31, 2025 report on Form 10-K under the heading "Non-GAAP Operating ROE" in the Executive Summary of Operations section for details on our calculation.  | <sup>(2)</sup> Quarterly amounts are annualized. Refer to our December 31, 2025 report on Form 10-K under the heading "Non-GAAP Operating ROE" in the Executive Summary of Operations section for details on our calculation.  | <sup>(2)</sup> Quarterly amounts are annualized. Refer to our December 31, 2025 report on Form 10-K under the heading "Non-GAAP Operating ROE" in the Executive Summary of Operations section for details on our calculation.  | <sup>(2)</sup> Quarterly amounts are annualized. Refer to our December 31, 2025 report on Form 10-K under the heading "Non-GAAP Operating ROE" in the Executive Summary of Operations section for details on our calculation.  |

---

**SPECIALTY P&C SEGMENT RESULTS**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** |
| ($ in thousands) | **<u>2025</u>** | <u>2024</u> | *<u>% Change</u>* | **<u>2025</u>** | <u>2024</u> | *<u>% Change</u>* |
| Gross premiums written | $**155815** | $161561 | *(3.6 %)* | $**776942** | $807463 | *(3.8 %)* |
| Net premiums written | $**143560** | $148293 | *(3.2 %)* | $**705768** | $737502 | *(4.3 %)* |
| Net premiums earned | $**180846** | $185805 | *(2.7 %)* | $**724198** | $747942 | *(3.2 %)* |
| Other income (expense) | **(583)** | 1605 | *(136.3 %)* | **6321** | 6588 | *(4.1 %)* |
| Total revenues | **180263** | 187410 | *(3.8 %)* | **730519** | 754530 | *(3.2 %)* |
| Net losses and loss adjustment expenses | **(94037)** | (143924) | *(34.7 %)* | **(519375)** | (578486) | *(10.2 %)* |
| Underwriting, policy acquisition and operating expenses | **(53870)** | (49994) | *7.8 %* | **(200436)** | (204142) | *(1.8 %)* |
| Total expenses | **(147907)** | (193918) | *(23.7 %)* | **(719811)** | (782628) | *(8.0 %)* |
| Segment results | $**32356** | $(6508) | *597.2 %* | $**10708** | $(28098) | *138.1 %* |

---

&nbsp;&nbsp;&nbsp;&nbsp;- more -&nbsp;&nbsp;&nbsp;&nbsp;Page: 3

------

**NEWS RELEASE CONTINUES**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **SPECIALTY P&C SEGMENT NON-GAAP ADJUSTED KEY RATIOS**<sup>(1)</sup> | **SPECIALTY P&C SEGMENT NON-GAAP ADJUSTED KEY RATIOS**<sup>(1)</sup> | **SPECIALTY P&C SEGMENT NON-GAAP ADJUSTED KEY RATIOS**<sup>(1)</sup> | **SPECIALTY P&C SEGMENT NON-GAAP ADJUSTED KEY RATIOS**<sup>(1)</sup> | **SPECIALTY P&C SEGMENT NON-GAAP ADJUSTED KEY RATIOS**<sup>(1)</sup> |
| | **Three Months Ended December 31** | **Three Months Ended December 31** | **Year Ended December 31** | **Year Ended December 31** |
|  | **<u>2025</u>** | <u>2024</u> | **<u>2025</u>** | <u>2024</u> |
| Current accident year net loss ratio | **84.4%** | 83.6% | **83.3%** | 83.1% |
| Effect of prior accident years' reserve development | **(34.5** **%)** | (10.3%) | **(12.7** **%)** | (6.5%) |
| Net loss ratio | **49.9%** | 73.3% | **70.6%** | 76.6% |
| Underwriting expense ratio | **30.0%** | 26.6% | **27.7%** | 27.3% |
| Combined ratio | **79.9%** | 99.9% | **98.3%** | 103.9% |

---

<sup>(1)</sup> Represents Non-GAAP financial measures. See a reconciliation to their GAAP counterparts under the heading "Non-GAAP Adjusted Key Ratios" that follows.

**WORKERS' COMPENSATION INSURANCE SEGMENT RESULTS**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** |
| ($ in thousands) | **<u>2025</u>** | <u>2024</u> | *<u>% Change</u>* | **<u>2025</u>** | <u>2024</u> | *<u>% Change</u>* |
| Gross premiums written | $**45702** | $46112 | *(0.9 %)* | $**235763** | $243404 | *(3.1 %)* |
| Net premiums written | $**30887** | $29559 | *4.5 %* | $**167258** | $166223 | *0.6 %* |
| Net premiums earned | $**40313** | $42918 | *(6.1 %)* | $**164351** | $167610 | *(1.9 %)* |
| Other income (expense) | **819** | 403 | *103.2 %* | **2056** | 1887 | *9.0 %* |
| Total revenues | **41132** | 43321 | *(5.1 %)* | **166407** | 169497 | *(1.8 %)* |
| Net losses and loss adjustment expenses | **(31767)** | (32503) | *(2.3 %)* | **(123795)** | (128483) | *(3.6 %)* |
| Underwriting, policy acquisition and operating expenses | **(15112)** | (17990) | *(16.0 %)* | **(63295)** | (61999) | *2.1 %* |
| Total expenses | **(46879)** | (50493) | *(7.2 %)* | **(187090)** | (190482) | *(1.8 %)* |
| Segment results | $**(5747)** | $(7172) | *19.9 %* | $**(20683)** | $(20985) | *1.4 %* |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **WORKERS' COMPENSATION INSURANCE SEGMENT KEY RATIOS** | **WORKERS' COMPENSATION INSURANCE SEGMENT KEY RATIOS** | **WORKERS' COMPENSATION INSURANCE SEGMENT KEY RATIOS** | **WORKERS' COMPENSATION INSURANCE SEGMENT KEY RATIOS** | **WORKERS' COMPENSATION INSURANCE SEGMENT KEY RATIOS** |
| | **Three Months Ended December 31** | **Three Months Ended December 31** | **Year Ended December 31** | **Year Ended December 31** |
|  | **<u>2025</u>** | <u>2024</u> | **<u>2025</u>** | <u>2024</u> |
| Current accident year net loss ratio | **83.0%** | 77.0% | **77.0%** | 77.0% |
| Effect of prior accident years' reserve development | **(4.2** **%)** | (1.3%) | **(1.7** **%)** | (0.3%) |
| Net loss ratio | **78.8%** | 75.7% | **75.3%** | 76.7% |
| Underwriting expense ratio | **37.5%** | 41.9% | **38.5%** | 37.0% |
| Combined ratio | **116.3%** | 117.6% | **113.8%** | 113.7% |

---

&nbsp;&nbsp;&nbsp;&nbsp;- more -&nbsp;&nbsp;&nbsp;&nbsp;Page: 4

------

**NEWS RELEASE CONTINUES**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT RESULTS** | **SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT RESULTS** | **SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT RESULTS** | **SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT RESULTS** | **SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT RESULTS** | **SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT RESULTS** | **SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT RESULTS** |
| | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** |
| ($ in thousands) | **<u>2025</u>** | <u>2024</u> | *<u>% Change</u>* | **<u>2025</u>** | <u>2024</u> | *<u>% Change</u>* |
| Gross premiums written | $**11051** | $12437 | *(11.1 %)* | $**51052** | $57904 | *(11.8 %)* |
| Net premiums written | $**9437** | $10693 | *(11.7 %)* | $**43887** | $49950 | *(12.1 %)* |
| Net premiums earned | $**10990** | $12351 | *(11.0 %)* | $**45687** | $52698 | *(13.3 %)* |
| Net investment income | **1046** | 921 | *13.6 %* | **3864** | 3608 | *7.1 %* |
| Net investment gains (losses) | **480** | 42 | *1042.9 %* | **2259** | 2369 | *(4.6 %)* |
| Other income (expense) | **7** | 18 | *(61.1 %)* | **25** | 19 | *31.6 %* |
| Net losses and loss adjustment expenses | **(3516)** | (5983) | *(41.2 %)* | **(22248)** | (32466) | *(31.5 %)* |
| Underwriting, policy acquisition and operating expenses | **(3888)** | (3959) | *(1.8 %)* | **(16128)** | (18063) | *(10.7 %)* |
| SPC U.S. federal income tax (expense) benefit <sup>(1)</sup> | **(501)** | (724) | *(30.8 %)* | **(2413)** | (1766) | *36.6 %* |
| SPC net results | **4618** | 2666 | *73.2 %* | **11046** | 6399 | *72.6 %* |
| SPC dividend (expense) income <sup>(2)</sup> | **(3112)** | (1965) | *58.4 %* | **(6873)** | (4444) | *54.7 %* |
| Segment results <sup>(3)</sup> | $**1506** | $701 | *114.8 %* | $**4173** | $1955 | *113.5 %* |
| <sup>(1)</sup> Represents the provision for U.S. federal income taxes for SPCs at Inova Re, which have elected to be taxed as a U.S. corporation under Section 953(d) of the Internal Revenue Code. U.S. federal income taxes are included in the total SPC net results and are paid by the individual SPCs.  | <sup>(1)</sup> Represents the provision for U.S. federal income taxes for SPCs at Inova Re, which have elected to be taxed as a U.S. corporation under Section 953(d) of the Internal Revenue Code. U.S. federal income taxes are included in the total SPC net results and are paid by the individual SPCs.  | <sup>(1)</sup> Represents the provision for U.S. federal income taxes for SPCs at Inova Re, which have elected to be taxed as a U.S. corporation under Section 953(d) of the Internal Revenue Code. U.S. federal income taxes are included in the total SPC net results and are paid by the individual SPCs.  | <sup>(1)</sup> Represents the provision for U.S. federal income taxes for SPCs at Inova Re, which have elected to be taxed as a U.S. corporation under Section 953(d) of the Internal Revenue Code. U.S. federal income taxes are included in the total SPC net results and are paid by the individual SPCs.  | <sup>(1)</sup> Represents the provision for U.S. federal income taxes for SPCs at Inova Re, which have elected to be taxed as a U.S. corporation under Section 953(d) of the Internal Revenue Code. U.S. federal income taxes are included in the total SPC net results and are paid by the individual SPCs.  | <sup>(1)</sup> Represents the provision for U.S. federal income taxes for SPCs at Inova Re, which have elected to be taxed as a U.S. corporation under Section 953(d) of the Internal Revenue Code. U.S. federal income taxes are included in the total SPC net results and are paid by the individual SPCs.  | <sup>(1)</sup> Represents the provision for U.S. federal income taxes for SPCs at Inova Re, which have elected to be taxed as a U.S. corporation under Section 953(d) of the Internal Revenue Code. U.S. federal income taxes are included in the total SPC net results and are paid by the individual SPCs.  |
| <sup>(2)</sup> Represents the net (profit) loss attributable to external cell participants. | <sup>(2)</sup> Represents the net (profit) loss attributable to external cell participants. | <sup>(2)</sup> Represents the net (profit) loss attributable to external cell participants. | <sup>(2)</sup> Represents the net (profit) loss attributable to external cell participants. | <sup>(2)</sup> Represents the net (profit) loss attributable to external cell participants. | <sup>(2)</sup> Represents the net (profit) loss attributable to external cell participants. | <sup>(2)</sup> Represents the net (profit) loss attributable to external cell participants. |
| <sup>(3)</sup> Represents our share of the net profit (loss) and OCI of the SPCs in which we participate. | <sup>(3)</sup> Represents our share of the net profit (loss) and OCI of the SPCs in which we participate. | <sup>(3)</sup> Represents our share of the net profit (loss) and OCI of the SPCs in which we participate. | <sup>(3)</sup> Represents our share of the net profit (loss) and OCI of the SPCs in which we participate. | <sup>(3)</sup> Represents our share of the net profit (loss) and OCI of the SPCs in which we participate. | <sup>(3)</sup> Represents our share of the net profit (loss) and OCI of the SPCs in which we participate. | <sup>(3)</sup> Represents our share of the net profit (loss) and OCI of the SPCs in which we participate. |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT KEY RATIOS** | **SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT KEY RATIOS** | **SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT KEY RATIOS** | **SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT KEY RATIOS** | **SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT KEY RATIOS** |
| | **Three Months Ended December 31** | **Three Months Ended December 31** | **Year Ended December 31** | **Year Ended December 31** |
|  | **<u>2025</u>** | <u>2024</u> | **<u>2025</u>** | <u>2024</u> |
| Current accident year net loss ratio | **56.4%** | 58.1% | **65.8%** | 66.8% |
| Effect of prior accident years' reserve development | **(24.4** **%)** | (9.7%) | **(17.1** **%)** | (5.2%) |
| Net loss ratio | **32.0%** | 48.4% | **48.7%** | 61.6% |
| Underwriting expense ratio | **35.4%** | 32.1% | **35.3%** | 34.3% |
| Combined ratio | **67.4%** | 80.5% | **84.0%** | 95.9% |

---

&nbsp;&nbsp;&nbsp;&nbsp;- more -&nbsp;&nbsp;&nbsp;&nbsp;Page: 5

------

**NEWS RELEASE CONTINUES**

**CORPORATE SEGMENT** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** |
| ($ in thousands) | **<u>2025</u>** | <u>2024</u> | *<u>% Change</u>* | **<u>2025</u>** | <u>2024</u> | *<u>% Change</u>* |
| Net investment income | **39126** | 35890 | *9.0 %* | **152634** | 140930 | *8.3 %* |
| Equity in earnings (loss) of unconsolidated subsidiaries: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;All other investments, primarily investment fund LPs/LLCs | **2895** | 4986 | *(41.9 %)* | **15443** | 21532 | *(28.3 %)* |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax credit partnerships | **51** | 834 | *(93.9 %)* | **833** | 671 | *24.1 %* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity in earnings (loss) of unconsolidated subsidiaries: | **2946** | 5820 | *(49.4 %)* | **16276** | 22203 | *(26.7 %)* |
| Net investment gains (losses) | **(5341)** | (3285) | *(62.6 %)* | **(7745)** | (7206) | *(7.5 %)* |
| Other income (expense) | **(773)** | 8160 | *(109.5 %)* | **(10813)** | 6820 | *(258.5 %)* |
| Operating expenses<sup>(1)</sup> | **(10486)** | (9532) | *10.0 %* | **(35292)** | (36619) | *(3.6 %)* |
| Interest expense | **(5218)** | (5339) | *(2.3 %)* | **(20838)** | (22342) | *(6.7 %)* |
| Income tax (expense) benefit<sup>(1)</sup> | **(13227)** | (2566) | *415.5 %* | **(22229)** | (10401) | *113.7 %* |
| Segment results | **7027** | 29148 | *(75.9 %)* | **71993** | 93385 | *(22.9 %)* |
| Consolidated effective tax rate | **28.4%** | 13.7% |  | **29.4%** | 16.4% |  |

---

<sup>(1)</sup> Our Corporate segment results for the quarter and year ended December 31, 2025 exclude pre-tax transaction-related costs of $1.8 million and $16.4 million, respectively, and the associated income tax benefit related to the proposed merger transaction with The Doctors Company. Our Corporate segment results for the year ended December 31, 2024 exclude pre-tax transaction-related costs of $0.3 million and the associated income tax benefit attributable to actuarial consulting fees paid during the second quarter of 2024 in relation to the final determination of contingent consideration associated with the NORCAL acquisition. These costs are excluded as we do not consider these items in assessing the financial performance of the segment. Additional information regarding the proposed merger transaction with The Doctors Company is provided in Note 1 of the Notes to the Consolidated Financial Statements in our December 31, 2025 report on Form 10-K.

&nbsp;&nbsp;&nbsp;&nbsp;- more -&nbsp;&nbsp;&nbsp;&nbsp;Page: 6

------

**NEWS RELEASE CONTINUES**

**NON-GAAP FINANCIAL MEASURES**

**<u>Non-GAAP Operating Income (Loss)</u>**

Non-GAAP operating income (loss) is a financial measure that is widely used to evaluate performance within the insurance sector. In calculating Non-GAAP operating income (loss), we have excluded the effects of the items listed in the following table that do not reflect normal results. We believe Non-GAAP operating income (loss) presents a useful view of the performance of our ongoing core insurance operations; however, it should be considered in conjunction with net income (loss) computed in accordance with GAAP. The following table is a reconciliation of net income (loss) to Non-GAAP operating income (loss):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **RECONCILIATION OF NET INCOME (LOSS) TO NON-GAAP OPERATING INCOME (LOSS)** | **RECONCILIATION OF NET INCOME (LOSS) TO NON-GAAP OPERATING INCOME (LOSS)** | **RECONCILIATION OF NET INCOME (LOSS) TO NON-GAAP OPERATING INCOME (LOSS)** | **RECONCILIATION OF NET INCOME (LOSS) TO NON-GAAP OPERATING INCOME (LOSS)** | **RECONCILIATION OF NET INCOME (LOSS) TO NON-GAAP OPERATING INCOME (LOSS)** |
| | **Three Months Ended December 31** | **Three Months Ended December 31** | **Year Ended December 31** | **Year Ended December 31** |
| (In thousands, except per share data) | **<u>2025</u>** | <u>2024</u> | **<u>2025</u>** | <u>2024</u> |
| Net income (loss) | $**33369** | $16169 | $**50915** | $52744 |
| Items excluded in the calculation of Non-GAAP operating income (loss): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment (gains) losses <sup>(1)</sup> | **4861** | 3243 | **5486** | (1903) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment gains (losses) attributable to SPCs in which no profit/loss is retained <sup>(2)</sup> | **347** | 30 | **1585** | 1773 |
| &nbsp;&nbsp;&nbsp;&nbsp;Transaction-related costs <sup>(3)</sup> | **1773** |  | **16351** | 320 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency exchange rate (gains) losses <sup>(4)</sup> | **841** | (8140) | **10882** | (6731) |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-operating income <sup>(5)</sup> | **—** |  | **(3162)** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Guaranty fund assessments (recoupments) | **(517)** | (2) | **(491)** | (873) |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-core operations <sup>(6)</sup> | **2844** | 7879 | **6382** | 5330 |
| Pre-tax effect of exclusions | **10149** | 3010 | **37033** | (2084) |
| Tax effect, at 21% <sup>(7)</sup> | **(1129)** | 565 | **(4085)** | (489) |
| &nbsp;&nbsp;&nbsp;&nbsp;After-tax effect of exclusions | **9020** | 3575 | **32948** | (2573) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP operating income (loss) | $**42389** | $19744 | $**83863** | $50171 |
| &nbsp;&nbsp;&nbsp;&nbsp;Per diluted common share: |  |  |  |  |
| Net income (loss) | $**0.64** | $0.31 | $**0.99** | $1.03 |
| Effect of exclusions | **0.18** | 0.07 | **0.63** | (0.05) |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP operating income (loss) per diluted common share | $**0.82** | $0.38 | $**1.62** | $0.98 |

---

<sup>(1)</sup> Net investment gains (losses) recognized in earnings are primarily driven by changes in the value of investments that are marked to fair value each period, the nature and timing of which are unrelated to our normal operating results. In addition, net investment gains (losses) for the year ended December 31, 2024 include the $6.5 million decrease to the contingent consideration liability.

<sup>(2)</sup> Net investment gains (losses) on investments related to SPCs are recognized in our Segregated Portfolio Cell Reinsurance segment. SPC results, including any net investment gain or loss, that are attributable to external cell participants are reflected in the SPC dividend expense (income). To be consistent with our exclusion of net investment gains (losses) recognized in earnings, we are excluding the portion of net investment gains (losses) that is included in the SPC dividend expense (income) which is attributable to the external cell participants.

<sup>(3)</sup> Transaction-related costs in 2025 are attributable to professional fees incurred in relation to the proposed merger transaction with The Doctors Company. Additional information regarding the proposed merger transaction with The Doctors Company is provided in Note 1 of the Notes to the Consolidated Financial Statements in our December 31, 2025 report on Form 10-K. Transaction-related costs in 2024 are attributable to actuarial consulting fees paid during the second quarter of 2024 in relation to the final determination of contingent consideration associated with the NORCAL acquisition. We are excluding these costs as they do not reflect normal operating results and are unique and non-recurring in nature.

<sup>(4)</sup> Foreign currency exchange rate gains (losses) are reported in our Corporate segment and are primarily related to foreign currency denominated balances associated with international insurance exposures, primarily related to our strategic partnership with an international medical professional liability insured in our Specialty P&C segment. Due to the size of the loss reserves associated with these international exposures, even nominal movements in exchange rates can lead to volatility in our results of operations. We exclude foreign currency exchange rate movements as the nature and timing of these changes are not indicative of our normal core operating results. Additional information on foreign currency exchange rate gains (losses) is provided in the Executive Summary of Operations section under the heading "Revenues" in our December 31, 2025 report on Form 10-K.

<sup>(5)</sup> Non-operating income reflects proceeds of $1.0 million associated with the sale of the renewal rights related to our legal professional liability book of business to an unrelated third party in the second quarter of 2025 and a gain of $2.2 million associated with the sale of our Franklin, TN property to an unrelated third party in the first quarter of 2025. Additional information regarding the legal professional liability transaction is provided in Part I Item 1. Business under the heading "Specialty Property and Casualty Segment" in our December 31, 2025 report on Form 10-K. We are excluding these items as they do not reflect normal operating results and are unique and non-recurring in nature.

&nbsp;&nbsp;&nbsp;&nbsp;- more -&nbsp;&nbsp;&nbsp;&nbsp;Page: 7

------

**NEWS RELEASE CONTINUES**

<sup>(6)</sup> Non-core operations include the net underwriting results from operations that are currently in run-off but do not qualify for Discontinued Operations accounting treatment under GAAP. These operations include our Lloyd's Syndicates operations from our previous participation in Syndicate 1729 and Syndicate 6131 as well as our legal professional liability book of business. Net investment gains (losses) recognized in earnings associated with these operations are included in the adjustment for consolidated net investment gains (losses) as described in footnote 1.

<sup>(7)</sup> Our statutory tax rate (21%) was applied to these items in calculating net income (loss). Changes in the contingent consideration liability are non-taxable and therefore have no associated income tax impact. The taxes associated with the net investment gains (losses) related to SPCs in our Segregated Portfolio Cell Reinsurance segment are paid by the individual SPCs and are not included in our consolidated tax provision or net income (loss); therefore, both the net investment gains (losses) from our Segregated Portfolio Cell Reinsurance segment and the adjustment to exclude the portion of net investment gains (losses) included in the SPC dividend expense (income) in the table above are not tax effected. There are no taxes associated with our Lloyd's Syndicates operations in our consolidated tax provision due to the availability of net operating losses and the full valuation allowance recorded against the deferred tax assets. Accordingly, all adjustments related to our Lloyd's Syndicates operations in the table above are not tax effected. The portion of transaction-related costs that is tax deductible was tax effected at the statutory tax rate while the remaining non-deductible portion was not tax effected as there was no associated income tax benefit.

**<u>Non-GAAP Adjusted Key Ratios</u>**

Certain key performance ratios include the impact of certain before-tax effects of items that do not reflect normal operating results, as discussed in the previous table. We believe adjusting our key ratios for these items presents a useful view of the performance of our ongoing core insurance operations; however, it should be considered in conjunction with ratios computed in accordance with GAAP.

Our consolidated key ratios for the quarter and year ended December 31, 2025 and 2024 include the impact of net underwriting results related to non-core operations, guaranty fund assessments and transaction-related costs (see previous discussion on these items in the previous table). Non-core operations include an underwriting loss of $3.4 million and $8.1 million for the quarter and year ended December 31, 2025, respectively, associated with our Lloyd's Syndicates operations as compared to an underwriting loss of $6.3 million and $4.7 million for the same respective periods of 2024. Also included in non-core operations for the quarter and year ended December 2024 is a nominal amount of underwriting income associated with our legal professional liability book of business as compared to an underwriting loss of $1.9 million and $2.0 million for the same respective periods of 2024.

The following table is a reconciliation of our consolidated key ratios to Non-GAAP adjusted key ratios for the quarter and year ended December 31, 2025 and 2024:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** |
| **CONSOLIDATED** | **<u>2025</u>** | **<u>2025</u>** | **<u>2025</u>** | **<u>2025</u>** | <u>2024</u> | <u>2024</u> | <u>2024</u> | <u>2024</u> |
|  | **As Reported** | *Non-GAAP operating adjustments* | *Non-GAAP operating adjustments* | Non-GAAP Adjusted Ratios | As Reported | *Non-GAAP operating adjustments* | *Non-GAAP operating adjustments* | Non-GAAP Adjusted Ratios |
| Current accident year net loss ratio | **81.7%** | *1.1* | *pts* | 82.8% | 80.4% | *0.6* | *pts* | 81.0% |
| Effect of prior accident years' reserve development | **(26.0** **%)** | *(2.7* | *pts)* | (28.7%) | (4.7%) | *(3.9* | *pts)* | (8.6%) |
| Net loss ratio | **55.7%** | *(1.6* | *pts)* | 54.1% | 75.7% | *(3.3* | *pts)* | 72.4% |
| Underwriting expense ratio | **36.6%** | *(0.4* | *pts)* | 36.2% | 33.6% | *—* | *pts* | 33.6% |
| Combined ratio | **92.3%** | *(2.0* | *pts)* | 90.3% | 109.3% | *(3.3* | *pts)* | 106.0% |
| Less: investment income ratio | **17.3%** | *—* | *pts* | 17.3% | 15.3% | *0.2* | *pts* | 15.5% |
| Operating ratio | **75.0%** | *(2.0* | *pts)* | 73.0% | 94.0% | *(3.5* | *pts)* | 90.5% |

---

&nbsp;&nbsp;&nbsp;&nbsp;- more -&nbsp;&nbsp;&nbsp;&nbsp;Page: 8

------

**NEWS RELEASE CONTINUES**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** |
| | **<u>2025</u>** | **<u>2025</u>** | **<u>2025</u>** | **<u>2025</u>** | <u>2024</u> | <u>2024</u> | <u>2024</u> | <u>2024</u> |
|  | **As Reported** | *Non-GAAP operating adjustments* | *Non-GAAP operating adjustments* | Non-GAAP Adjusted Ratios | As Reported | *Non-GAAP operating adjustments* | *Non-GAAP operating adjustments* | Non-GAAP Adjusted Ratios |
| Current accident year net loss ratio | **80.9%** | *0.4* | *pts* | 81.3% | 80.5% | *0.6* | *pts* | 81.1% |
| Effect of prior accident years' reserve development | **(9.7** **%)** | *(1.2* | *pts)* | (10.9%) | (4.1%) | *(1.2* | *pts)* | (5.3%) |
| Net loss ratio | **71.2%** | *(0.8* | *pts)* | 70.4% | 76.4% | *(0.6* | *pts)* | 75.8% |
| Underwriting expense ratio | **35.4%** | *(1.6* | *pts)* | 33.8% | 33.0% | *0.2* | *pts* | 33.2% |
| Combined ratio | **106.6%** | *(2.4* | *pts)* | 104.2% | 109.4% | *(0.4* | *pts)* | 109.0% |
| Less: investment income ratio | **16.8%** | *—* | *pts* | 16.8% | 14.9% | *0.4* | *pts* | 15.3% |
| Operating ratio | **89.8%** | *(2.4* | *pts)* | 87.4% | 94.5% | *(0.8* | *pts)* | 93.7% |

---

Our Specialty P&C segment key ratios for the quarter and year ended December 31, 2025 and 2024 include the impact of net underwriting results related to non-core operations, as previously discussed, and guaranty fund assessments.

The following table is a reconciliation of our Specialty P&C segment key ratios to Non-GAAP adjusted key ratios for the quarter and year ended December 31, 2025 and 2024:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** | **Three Months Ended December 31** |
| **SPECIALTY P&C SEGMENT** | **<u>2025</u>** | **<u>2025</u>** | **<u>2025</u>** | **<u>2025</u>** | <u>2024</u> | <u>2024</u> | <u>2024</u> | <u>2024</u> |
|  | **Segment As Reported** | *Non-GAAP operating adjustments* | *Non-GAAP operating adjustments* | Non-GAAP Adjusted Ratios | Segment As Reported | *Non-GAAP operating adjustments* | *Non-GAAP operating adjustments* | Non-GAAP Adjusted Ratios |
| Current accident year net loss ratio | **82.9%** | *1.5* | *pts* | 84.4% | 82.7% | *0.9* | *pts* | 83.6% |
| Effect of prior accident years' reserve development | **(30.9** **%)** | *(3.6* | *pts)* | (34.5%) | (5.2%) | *(5.1* | *pts)* | (10.3%) |
| Net loss ratio | **52.0%** | *(2.1* | *pts)* | 49.9% | 77.5% | *(4.2* | *pts)* | 73.3% |
| Underwriting expense ratio | **29.8%** | *0.2* | *pts* | 30.0% | 26.9% | *(0.3* | *pts)* | 26.6% |
| Combined ratio | **81.8%** | *(1.9* | *pts)* | 79.9% | 104.4% | *(4.5* | *pts)* | 99.9% |
|  | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** | **Year Ended December 31** |
|  | **<u>2025</u>** | **<u>2025</u>** | **<u>2025</u>** | **<u>2025</u>** | <u>2024</u> | <u>2024</u> | <u>2024</u> | <u>2024</u> |
|  | **Segment As Reported** | *Non-GAAP operating adjustments* | *Non-GAAP operating adjustments* | Non-GAAP Adjusted Ratios | Segment As Reported | *Non-GAAP operating adjustments* | *Non-GAAP operating adjustments* | Non-GAAP Adjusted Ratios |
| Current accident year net loss ratio | **82.7%** | *0.6* | *pts* | 83.3% | 82.3% | *0.8* | *pts* | 83.1% |
| Effect of prior accident years' reserve development | **(11.0** **%)** | *(1.7* | *pts)* | (12.7%) | (5.0%) | *(1.5* | *pts)* | (6.5%) |
| Net loss ratio | **71.7%** | *(1.1* | *pts)* | 70.6% | 77.3% | *(0.7* | *pts)* | 76.6% |
| Underwriting expense ratio | **27.7%** | *—* | *pts* | 27.7% | 27.3% | *—* | *pts* | 27.3% |
| Combined ratio | **99.4%** | *(1.1* | *pts)* | 98.3% | 104.6% | *(0.7* | *pts)* | 103.9% |

---

&nbsp;&nbsp;&nbsp;&nbsp;- more -&nbsp;&nbsp;&nbsp;&nbsp;Page: 9

------

**NEWS RELEASE CONTINUES**

**<u>Non-GAAP Operating ROE</u>**

The following table is a reconciliation of ROE to Non-GAAP operating ROE for the quarter and year ended December 31, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>December 31** | **Three Months Ended<br>December 31** | **Year Ended<br>December 31** | **Year Ended<br>December 31** |
| | **<u>2025</u>** | <u>2024</u> | **<u>2025</u>** | <u>2024</u> |
| ROE<sup>(1)</sup> | **10.1%** | 5.3% | **4.0%** | 4.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of items excluded in the calculation of Non-GAAP operating ROE | **2.7%** | 1.2% | **2.6%** | (0.2%) |
| Non-GAAP operating ROE | **12.8%** | 6.5% | **6.6%** | 4.4% |
| <sup>(1)</sup> Quarterly amounts are annualized. Refer to our December 31, 2025 report on Form 10-K under the heading "Non-GAAP Operating ROE" in the Executive Summary of Operations section for details on our calculation. | <sup>(1)</sup> Quarterly amounts are annualized. Refer to our December 31, 2025 report on Form 10-K under the heading "Non-GAAP Operating ROE" in the Executive Summary of Operations section for details on our calculation. | <sup>(1)</sup> Quarterly amounts are annualized. Refer to our December 31, 2025 report on Form 10-K under the heading "Non-GAAP Operating ROE" in the Executive Summary of Operations section for details on our calculation. | <sup>(1)</sup> Quarterly amounts are annualized. Refer to our December 31, 2025 report on Form 10-K under the heading "Non-GAAP Operating ROE" in the Executive Summary of Operations section for details on our calculation. | <sup>(1)</sup> Quarterly amounts are annualized. Refer to our December 31, 2025 report on Form 10-K under the heading "Non-GAAP Operating ROE" in the Executive Summary of Operations section for details on our calculation. |

---

**<u>Non-GAAP Adjusted Book Value per Share</u>**

The following table is a reconciliation of our book value per share to Non-GAAP adjusted book value per share at December 31, 2025 and December 31, 2024:

---

| | |
|:---|:---|
| | **Book Value Per Share** |
| Book Value Per Share at December 31, 2024 | $23.49 |
| &nbsp;&nbsp;&nbsp;Less: AOCI Per Share<sup>(1)</sup> | (3.37) |
| Non-GAAP Adjusted Book Value Per Share at December 31, 2024 | 26.86 |
| Increase (decrease) to Non-GAAP Adjusted Book Value Per Share during the year ended December 31, 2025 attributable to: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | **0.99** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other<sup>(2)</sup> | **(0.03)** |
| **Non-GAAP Adjusted Book Value Per Share at December 31, 2025** | **27.82** |
| &nbsp;&nbsp;&nbsp;Add: AOCI Per Share<sup>(1)</sup> | **(1.58)** |
| **Book Value Per Share at December 31, 2025** | $**26.24** |
| <sup>(1)</sup> Primarily the impact of accumulated unrealized investment gains (losses) on our available-for-sale fixed maturity investments. See Note 11 of the Notes to Consolidated Financial Statements in our December 31, 2025 report on Form 10-K for additional information. | <sup>(1)</sup> Primarily the impact of accumulated unrealized investment gains (losses) on our available-for-sale fixed maturity investments. See Note 11 of the Notes to Consolidated Financial Statements in our December 31, 2025 report on Form 10-K for additional information. |
| <sup>(2)</sup> Primarily the impact of an increase in common shares outstanding due to share-based compensation. | <sup>(2)</sup> Primarily the impact of an increase in common shares outstanding due to share-based compensation. |

---

**About ProAssurance**

ProAssurance Corporation is an industry-leading specialty insurer with extensive expertise in medical professional liability and products liability for medical technology and life sciences. The Company also is a provider of workers' compensation insurance in the eastern U.S. ProAssurance Group is rated "A" (Excellent) by AM Best.

For the latest on ProAssurance and its industry-leading suite of products and services, cutting-edge risk management and practice enhancement programs, visit our website at https://ProAssuranceGroup.com with investor content available at https://Investor.ProAssurance.com. Our YouTube channel regularly presents insightful videos that communicate effective practice management, patient safety and risk management strategies.

**Forward-Looking Statements**

The foregoing contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are often identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "hope," "hopeful," "likely," "may," "optimistic," "possible," "potential," "preliminary," "project," "should," "will," "would" or the negative or plural of these words or similar expressions or variations. Forward-looking statements are made based upon management's current expectations and beliefs and are not guarantees of future performance. Such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements. These factors include, among others: (i) the completion of the proposed transaction on the anticipated terms and timing, (ii) the satisfaction of other conditions to the completion of the proposed transaction, including obtaining required shareholder and regulatory approvals; (iii) the risk that ProAssurance Corporation's stock price may fluctuate during the pendency of the proposed transaction and may decline if the

&nbsp;&nbsp;&nbsp;&nbsp;- more -&nbsp;&nbsp;&nbsp;&nbsp;Page: 10

------

**NEWS RELEASE CONTINUES**

proposed transaction is not completed; (iv) potential litigation relating to the proposed transaction that could be instituted against ProAssurance Corporation or its directors, managers or officers, including the effects of any outcomes related thereto; (v) the risk that disruptions from the proposed transaction will harm ProAssurance Corporation's business, including current plans and operations, including during the pendency of the proposed transaction; (vi) the ability of ProAssurance Corporation to retain and hire key personnel; (vii) the diversion of management's time and attention from ordinary course business operations to completion of the proposed transaction and integration matters; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; (ix) legislative, regulatory and economic developments; (x) potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect ProAssurance Corporation's financial performance; (xi) certain restrictions during the pendency of the proposed transaction that may impact ProAssurance Corporation's ability to pursue certain business opportunities or strategic transactions; (xii) unpredictability and severity of catastrophic events, including but not limited to acts of terrorism, outbreaks of war or hostilities or global pandemics, as well as management's response to any of the aforementioned factors; (xiii) the possibility that the proposed transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (xiv) unexpected costs, liabilities or delays associated with the transaction; (xv) the response of competitors to the transaction; (xvi) the occurrence of any event, change or other circumstance that could give rise to the termination of the proposed transaction, including in circumstances requiring ProAssurance Corporation to pay a termination fee ; and (xvii) other risks set forth under the heading "Risk Factors," of our Annual Report on Form 10-K for the year ended December 31, 2024 and in our subsequent filings with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Our actual results could differ materially from the results described in or implied by such forward looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

#####

Page: 11